Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biorepair PERIBIOMA is a specialized oral care product line developed by Coswell, featuring the patented microRepair technology. This technology consists of zinc-substituted carbonate-hydroxyapatite microparticles that are biomimetically similar to the natural mineral components of tooth enamel and dentin. These microparticles bind to the tooth surface, filling micro-scratches and creating a protective layer that prevents acid erosion and reduces tooth sensitivity. The PERIBIOMA formulation is specifically enhanced with probiotics, such as Lactobacillus, to promote a balanced oral microbiome and protect against periodontal diseases like gingivitis. In clinical research, it has been studied for its ability to neutralize salivary pH after the consumption of acidic beverages, thereby mitigating the risk of dental caries and erosion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biorepair PERIBIOMA.